RADIATION ONCOLOGY

CASE REPORT

Open Access

Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of ^{131}I-MIBG

Samer Ezziddin[1*], Amir Sabet[1], Yon-Dschun Ko[2], Sunny Xun[1], Alexander Matthies[1] and Hans-Jürgen Biersack[1]

Abstract

^{131}I-MIBG therapy for neuroendocrine tumours may be dose limited. The common range of applied cumulative activities is 10-40 GBq. We report the uneventful cumulative administration of 111 GBq (= 3 Ci) ^{131}I-MIBG in a patient with metastatic paraganglioma. Ten courses of ^{131}I-MIBG therapy were given within six years, accomplishing symptomatic, hormonal and tumour responses with no serious adverse effects. Chemotherapy with cisplatin/vinblastine/dacarbazine was the final treatment modality with temporary control of disease, but eventually the patient died of progression. The observed cumulative activity of ^{131}I-MIBG represents the highest value reported to our knowledge, and even though 12.6 GBq of ^{90}Y-DOTATOC were added intermediately, no associated relevant bone marrow, hepatic or other toxicity were observed. In an individual attempt to palliate metastatic disease high cumulative activity alone should not preclude the patient from repeat treatment.

Keywords: Cumulative activity, I-131-MIBG, Neuroendocrine tumors, Radionuclide therapy, Metastatic paraganglioma

Background

Targeted radiotherapy with ^{131}I-metaiodobenzylguanidine (^{131}I-MIBG) provides a generally well tolerated treatment in chromaffin tumors; i.e. neuroblastoma, pheochromocytoma, and paraganglioma [1-4]. Hematotoxicity is the primary side effect depending on the administered activity, metastatic bone marrow infiltration and other performed treatment modalities as chemotherapy [5-7]. Treatment protocols mostly use activities between 3.7 and 11.1 GBq (100-300 mCi) per course [8,9]. Newer schedules use 14.8-18.5 GBq (400-500 mCi) per treatment course and high-dose concepts may incorporate an initial dose of > 22,2 GBq (600 mCi) supported by potential autologous stem-cell rescue (ASCR) [10,11].

However, there is no existing recommendation for repeat treatment or maximum cumulative activity. While the common total administered activity per patient varies between 10 and 40 GBq [9,12] occasional reports of higher values up to 70 GBq do exist [10,13-16]. One

patient with metastatic pheochromocytoma was noted to receive as much as 85.9 GBq (2321 mCi) ^{131}I-MIBG [17].

We report on a case of metastatic paraganglioma undergoing repetitive MIBG treatment during the course of disease, resulting in an extraordinary high cumulative activity of 3 Ci without any observed dose limiting toxicity.

Case presentation

A 52-year-old female with a highly functional retroperitoneal paraganglioma and previous tumorectomy was referred for ^{131}I-MIBG therapy in recurrent hepatic metastatic disease. The patient suffered from hypertension, tachycardia and sweating. ^{131}I-MIBG therapy was initiated after confirmation of tumor uptake in a diagnostic MIBG scan. The treatment was performed using 11.1 GBq (300 mCi) ^{131}I-MIBG of high specific activity (GE Healthcare, Amersham, Germany), given intravenously by slow infusion. The minimum interval between two courses of ^{131}I-MIBG was eight weeks. Drugs known to interfere with MIBG uptake were discontinued before admission to treatment [18]. Thyroid uptake of free radioiodine was blocked either by sodium perchlorate,

* Correspondence: samer.ezziddin@ukb.uni-bonn.de
[1]Department of Nuclear Medicine, University Hospital, Bonn, Germany
Full list of author information is available at the end of the article

600 mg p.o. three times a day, administered for 3-6 weeks (treatment cycle no.1-6) or by potassium iodide 100-200 mg per day plus levothyroxine 100 μg/d for 2-4 weeks (treatment cycle no. 7-10). Blood pressure and heart rate were monitored during ^{131}I-MIBG infusion. Posttherapeutic ^{131}I-MIBG imaging was performed four to six and eight to ten days after therapy, with whole body and planar scans using a dual head large-field-of-view gamma camera (Picker Prism 2000 XP, Philips Medical Technology, USA) with a high-energy collimator. Toxicity was evaluated by extensive laboratory tests including complete blood count and liver function tests. Treatment response was assessed by CT and MRI, posttherapeutic MIBG scintigraphy, 24-h urine sampling and monitoring of catecholamine-related symptoms. For radiographic tumour response the Response Evaluation Criteria of Solid Tumors (RECIST) criteria were applied. The MIBG scintigraphy was added for evaluation of bone metastases (classically non-measurable disease in RECIST), i.e. MIBG-positive bone metastases becoming MIBG-negative with accompanying sclerotic changes in CT were interpreted as non-vital. Biochemical response was classified as CR (complete response) in complete normalization and partial response (PR) in more than 50% reduction of catecholamine levels. Symptomatic response was categorized into complete (CR) and partial (PR) resolution of functional symptoms. The first four MIBG treatment courses-given within seven months-produced a gradual and increasing symptomatic, biochemical and radiographic tumour response corresponding with a partial remission (PR). Figure 1 shows the first posttherapeutic scan (a). Partial hepatectomy was performed and left the patient with no detectable residual tumor. The complete radiological and functional remission lasted almost two years, when the patient experienced a relapse with appearance of a few liver and lung metastases as well as a retroperitoneal tumour lesion (Figure 1, b).


Figure 1 Post-therapeutic ^{131}I-MIBG scans (anterior and posterior view) of the 1st (a) and 5th (b) therapy showing the well-accumulating metastases in the early to mid stages of the disease.

Four more courses of ^{131}I-MIBG (cycle no. 5-8) were subsequently given within one year. Following the sixth ^{131}I-MIBG cycle the sodium perchlorate used for thyroid blockade caused the patient fever, chills and a rash, and oral iodine (100 mg per day) was used instead thereafter. Again, a partial remission was achieved, but progression occurred less than one year later with development of a clinically predominant large metastatic liver lesion. Since this centrally located lesion proved unresectable during surgery, selective portal vein ligation of the affected liver segments was performed. This procedure was followed by two courses of Y-90-DOTATOC (performed at the University Hospital Basel, Switzerland, with a total dose of 12.6 GBq Y-90) after confirmation of tumour uptake in somatostatin receptor scintigraphy using ^{111}In-pentetreotide. The initial response was good (PR), but shortly later the patient experienced extensive multi-site disease progression. The results of the reassessment at that time with pre- and posttherapeutic scintigraphic imaging are depicted in Figure 2, showing widespread metastases. Since the concomitant scintigraphic somatostatin receptor evaluation showed no additional tumour lesions compared to the MIBG scan, there was no indication of dedifferentiation (loss of MIBG-accumulating) of tumour cells. At this advanced stage, only disease stabilization and symptomatic relief were achieved by another 2 MIBG treatment cycles, with tumour progression occurring after six months.

Then, the patient underwent chemotherapy with cyclophosphamide, vincristine and dacarbazine (CVD regimen) with temporary control of disease, but eventually died of progression. No dose limiting bone marrow toxicity was observed throughout and following chemotherapy. It should be mentioned that stem cell support was not available in this patient. Figure 3 gives an overview of the various treatment applications over the course of time including ^{131}I-MIBG with the resulting cumulative activity. The treatment response and hematologic toxicity of all ^{131}I-MIBG courses is given in Table 1. The only observed adverse effect was a mild to moderate bone marrow toxicity seen after some of the earlier courses of MIBG therapy. It might have been caused by the perchlorate medication used for thyroid blockade at therapy no. 1-6, as this agent is known to cause reversible leukopenia in higher doses as been used in our case [19]. It is noteworthy that no serious toxicity was observed throughout the entire life-span although the high administered dose met potential predisposing factors for liver failure such as previous partial hepatectomy, selective portal vein ligation and liver metastases.

Conclusions

We report the uncomplicated administration of 111 GBq (= 3 Ci) cumulative activity of ^{131}I-MIBG without

Figure 2 ^{123}I-MIBG (a) and ^{111}In-pentetreotide (b) scans before MIBG therapy no. 9, followed by the post-therapeutic ^{131}I-MIBG scan (c): Later stage metastases to the lungs, liver, lymph nodes, soft tissue and bone, still displaying avid tracer uptake. The ^{111}In-pentetreotide scan shows no additional lesions compared to the MIBG scans.


Figure 3 ^{131}I-MIBG cycles with the resulting cumulative activity and other treatments over the course of time.

Table 1 Treatment response and toxicity

Tumour lesions	Course of ^{131}I-MIBG (no.)	Toxicity leukopenia (grade[a])	Response			
			Sympt.	Bioch.	Radiol.	TTP[b]
three liver mets, one Ln met	1st	0	PR	PR	PR	33
	2nd	0	PR	PR	PR	33
	3rd	2	PR	PR	PR	33
	4th	1	PR	PR	PR	33
no tumour (CR) after surgery						
retroperit. tumour mass, liver and lung mets (< five each)	5th	0	CR	PR	PR	23
	6th	1	CR	PR	PR	23
	7th	1	CR	PR	PR	23
	8th	0	CR	PR	PR	23
PR in number and size						
multiple mets to the lungs, liver, bone, soft tissue, Ln	9th	0	PR	SD	SD	6
	10th	0	PR	SD	SD	6

a: common toxicity criteria (CTC); b: time to progression in months; CR: complete response; PR: partial response; SD: stable disease

serious toxicity. This case underscores the therapeutic potential of ^{131}I-MIBG therapy in metastatic disease as well as inter-individual dose-tolerance variability. This, to our knowledge, represents the highest reported value and compares to the outstanding cumulative activity of 85.9 GBq in one patient noted in a larger series before [17]. In an individual attempt to palliate metastatic disease high cumulative activity alone should not preclude the patient from repeat treatment.

Consent

Written informed consent for publication of this Case report and any accompanying images was obtained from the patient's relative. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Author details
[1]Department of Nuclear Medicine, University Hospital, Bonn, Germany.
[2]Internal Medicine, Johanniter Hospital, Bonn, Germany.

Authors' contributions
Conception and idea of the work: S.E., HJ.B.; Collection and assembly of data or imaging: S.X., A.M., S.E., YD.K.; Drafting of the article: S.E., A.S., HJ.B.; Critical article revision for important intellectual content: HJ.B., YD.K.. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

References
1. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB: The diagnosis and management of malignant phaeochromocytoma and paraganglioma. *Endocr Relat Cancer* 2007, **14**:569-585.
2. Garaventa A, Guerra P, Arrighini A, Bertolazzi L, Bestagno M, De Bernardi B, Lanino E, Villavecchia GP, Claudiani F: Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine. *Cancer* 1991, **67**:922-928.
3. Gedik GK, Hoefnagel CA, Bais E, Olmos RA: 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging* 2008, **35**:725-733.
4. Grunwald F, Ezziddin S: 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. *Semin Nucl Med* 2010, **40**:153-163.
5. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB: Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. *Clin Endocrinol (Oxf)* 2001, **55**:47-60.
6. Nwosu AC, Jones L, Vora J, Poston GJ, Vinjamuri S, Pritchard DM: Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. *Br J Cancer* 2008, **98**:1053-1058.
7. Sisson JC, Shapiro B, Hutchinson RJ, Carey JE, Zasadny KR, Zempel SA, Normolle DP: Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine. *Eur J Nucl Med* 1994, **21**:46-52.
8. Sywak MS, Pasieka JL, McEwan A, Kline G, Rorstad O: 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. *World J Surg* 2004, **28**:1157-1162.
9. Pasieka JL, McEwan AJ, Rorstad O: The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. *Surgery* 2004, **136**:1218-1226.
10. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P: Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. *J Clin Oncol* 2009, **27**:4162-4168.
11. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS Jr, Tyler DS, Olson JA Jr: Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. *Surgery* 2003, **134**:956-962, discussion 962-953.
12. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC: The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. *J Endocrinol Invest* 1997, **20**:648-658.
13. Lewington VJ, Zivanovic MA, Tristam M, McEwan AJ, Ackery DM: Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma. *J Nucl Biol Med* 1991, **35**:280-283.
14. Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA: High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. *Cancer* 2003, **98**:239-248.

15. Bomanji JB, Wong W, Gaze MN, Cassoni A, Waddington W, Solano J, Ell PJ: **Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy.** *Clin Oncol (R Coll Radiol)* 2003, **15**:193-198.
16. Troncone L, Rufini V: **131I-MIBG therapy of neural crest tumours (review).** *Anticancer Res* 1997, **17**:1823-1831.
17. Krempf M, Lumbroso J, Mornex R, Brendel AJ, Wemeau JL, Delisle MJ, Aubert B, Carpentier P, Fleury-Goyon MC, Gibold C, *et al*: **Use of m-[131I] iodobenzylguanidine in the treatment of malignant pheochromocytoma.** *J Clin Endocrinol Metab* 1991, **72**:455-461.
18. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE: **A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG).** *Nucl Med Commun* 1992, **13**:513-521.
19. Wolff J: **Perchlorate and the thyroid gland.** *Pharmacol Rev* 1998, **50**:89-105.